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Recent studies in breast cancer suggest that monitoring the isolated tumour cells (ITC) may be used as a surrogate marker to evaluate
the efficacy of systemic chemotherapy. In the present study, we have investigated the effects of preoperative chemotherapy on ITC in
the blood and bone marrow of patients with potentially resectable gastric cancer. After sorting out the CD45-positive cells, the
presence of ITC defined as cytokeratin-positive cells was examined before and after preoperative chemotherapy. The patients
received two courses of preoperative chemotherapy with cisplatin (100mgm
 2, day 1) and 5-fluorouracil (1000mgm
 2, days 1–5),
administered every 28 days. Fourteen of 32 (44%) patients initially diagnosed with ITC in blood and/or bone marrow were found to
be negative (responders) after preoperative chemotherapy (Po0.01). The incidence of ITC in bone marrow was also significantly
(Po0.01) reduced from 97 (31 of 32) to 53% (17 of 32). The difference between patients positive for ITC in the blood before
(n¼7, 22%) and after (n¼5, 16%) chemotherapy was statistically insignificant. The overall 3-year survival rates were 32 and 49% in
the responders and non-responders, respectively (P¼0.683). These data indicate that preoperative chemotherapy can reduce the
incidence of ITC in patients with gastric cancer.
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Isolated tumour cells (ITC) in blood and bone marrow of cancer
patients are observed even in early stage disease (Maehara et al,
1998). Although their prognostic and predictive applications have
been thoroughly examined in patients with breast cancer, the exact
nature of ITC in gastric cancer remains to be determined.
Depending on the methods used, ITC are detected in up to 42
and 80% of blood and bone marrow samples, respectively
(Bonavina et al, 2001; Chen et al, 2004). Moreover, surgical
manoeuvres increase detection rates of ITC in many malignancies,
including gastric cancer and thus preoperative evaluation seems to
reflect more accurately the actual extent of the disease (Miyazono
et al, 2001; Ikeguchi and Kaibara, 2005).
There is a growing body of evidence that chemotherapy may
affect the outcomes of patients with resectable gastric cancer
(Carrato et al, 2005). However, unlike tumour response criteria in
unresectable cancer, no reliable surrogate markers permitting the
immediate assessment of the efficacy of chemotherapy have been
developed so far. The idea of using ITC as such a marker is gaining
an increasing attention since verification of other potential
compartments for cancer cells, for example, lymph nodes, is
usually impossible before surgery. The hypothesis that monitoring
the presence of ITC after chemotherapy may be clinically
justifiable has been recently verified in breast cancer and has
produced promising results (Slade et al, 2005; Drageset et al, 2006;
Fehm et al, 2006). No such observations are available for resectable
gastric cancer so far.
The purpose of this study was to investigate the effects of
preoperative chemotherapy on the presence of ITC in blood and
bone marrow of patients with potentially resectable gastric cancer.
MATERIALS AND METHODS
Patients
Two hundred and sixty-eight patients with gastric cancer admitted
between 2001 and 2005 were examined for the presence of ITC in
blood and bone marrow (Popiela et al, 2005). Thirty-two
consecutive patients positive for ITC in either blood or bone
marrow and diagnosed with a potentially resectable tumour were
selected for this study. There were 21 (66%) males and 11 (34%)
females with a median age of 62 years (95% confidence interval
(CI) 56–64). In all cases, the preoperative diagnosis of adeno-
carcinoma of the stomach was confirmed by gastroscopic biopsy.
The Bioethics Committee of the Jagiellonian University approved
the protocol of this study and all patients gave informed consent
before taking part in the study.
Chemotherapy
All patients received two courses of preoperative chemotherapy
with cisplatin and 5-fluorouracil (5-FU), administered every 28
days. Each cycle consisted of continuous intravenous infusion of
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s5-FU for 5 days at a dose of 1000mgm
 2 and intravenous cisplatin
on day 1 at a dose of 100mgm
 2. Within 21 days from the
completion of preoperative chemotherapy, all patients were
scheduled for gastrectomy. At laparotomy, the primary lesion
was found unresectable in five cases (peritoneal spread in four
patients and infiltration of coeliac trunk in one patient), while the
remaining 27 patients underwent gastric resection. Nineteen of
these patients received another two cycles of postoperative
chemotherapy. The remaining eight were not given chemotherapy
due to non-advanced lesions (stage IA n¼4, stage IB n¼2) or
poor performance status following surgery (n¼2).
Detection of ITC
Peripheral blood samples (20ml) and bone marrow aspirates
(5ml) from the iliac crest were taken before chemotherapy and
immediately before surgery. Control blood samples were collected
from clinically healthy blood donors (n¼8) and bone marrow
from patients with suspected idiopathic thrombocytopaenia
(n¼8). Pelleted cells from blood and bone marrow samples were
incubated with an excessive amount of lysing solution (Becton
Dickinson Biosciences, San Jose, CA, USA) for 10min, repeated
3–4 times to remove erythrocytes. The remaining cells were
washed in phosphate-buffered saline (PBS) and adjusted to the
concentration of 1 10
7cellsml
 1 in PBS. Subsequently, the cells
were stained with monoclonal mouse anti-human CD45 (phyco-
erythrin labelled) antibodies (DAKO, Glostrup, Denmark) and
sorted into CD45
þ and CD45
  populations using flow cytometry
(FACS Vantage SE, BD Biosciences, Bedford, MA, USA) equipped
with the TurboSort (BD Biosciences) option and Aerosol Protec-
tion System (Flexoduct International ApS, Greve, Denmark). The
Innova Enterprise II ion laser (Coherent, Santa Clara, CA, USA)
operating at 488nm was used as a light source. Sorting was
performed using a 70mm nozzle tip with a drop drive frequency of
65kHz, 1.5-drop envelopes and a ‘normal’ sorting mode. Sorted
CD45
  cells were collected into polystyrene Falcon 2057 tubes (BD
Biosciences) precoated with fetal calf serum and maintained in a
refrigerated bath recirculator (Neslab Instruments, Portsmouth,
NH, USA). About 1 10
6 of CD45
  cells (1 10
6cellsml
 1) were
used to prepare slides. The slides were dried, fixed with a mixture
of ethanol and acetone (1:1 vv
 1), and then stained for 30min
with A45-B/B3 monoclonal antibodies (5mgml
 1) (Micromet
GmbH, Germany), which recognise common epitopes of cytoker-
atins (CK) including CK 8, 18 and 19. Subsequently, the slides were
washed and stained for 30min with goat anti-mouse IgG-FITC-
labelled antibodies (DAKO). After washing with PBS, the slides
were assayed within 2 days. The CK
þ cells were identified by two
independent investigators under a BX60 fluorescent microscope
(Olympus, Tokyo, Japan) and documented with a DP10 camera
(Olympus). At least 300 cells were examined per slide. The samples
were regarded as positive when at least three CK
þ cells were found
per slide. Accordingly, patients were classified into CK
þ and CK
 
groups. After two cycles of chemotherapy, patients negative for
CK
þ cells, both in blood and bone marrow, were regarded as
responders. Non-responders were classified as the presence of
CK
þ cells in either blood or bone marrow.
Statistical analysis
The w
2 test or the Mann–Whitney U-test was used to detect
differences between the groups with regard to categorical or
ordinal parameters, respectively. Survival data were analysed
according to the Kaplan–Meier method and the log-rank test
was used to detect differences between individual groups. The
differences at Po0.05 were regarded as statistically significant.
Statistical analysis was performed using the SPSS v.14 (SPSS Inc.,
Chicago, IL, USA) software package.
RESULTS
Bone marrow status preoperatively and during follow-up
A detailed description of ITC before and after preoperative
chemotherapy is shown in Table 1. Isolated tumour cells were
eradicated in four of seven patients initially presenting with CK
þ
cells in blood. However, three patients negative for tumour cells in
blood before chemotherapy were subsequently found to be CK
þ.
Fifteen of 31 patients with ITC in bone marrow became CK
  and
only one patient changed his status from CK
  to CK
þ. The overall
response rate was 44% since 14 of 32 patients initially diagnosed
with ITC in the blood and/or bone marrow were found to be CK
 
after preoperative chemotherapy. There were no chemotherapy-
related deaths and no patient developed grade 3 or 4 toxicity as
defined by the WHO criteria.
Except a higher incidence of diffuse-type cancers in the
responders group (11 of 14 vs 7 of 18, P¼0.024), there were no
significant differences between responders and non-responders
with respect to the clinicopathological variables (Table 2). The
median follow-up period was 15.3 months (95% CI 9.7–28.4) and
17 patients died within 36 months following surgery (Figure 1). The
overall 3-year survival rates were 32 and 49% in the responders’
and non-responders’ groups and the corresponding median
survival time was 22.6 and 20.3 months, respectively (P¼0.683).
DISCUSSION
The results of the present study support an accumulating body of
evidence indicating that ITC in blood and/or bone marrow can be
found in patients with either early or advanced gastric cancer.
However, unlike other reports, we have specifically demonstrated
that preoperative chemotherapy with cisplatin and 5-FU signifi-
cantly reduces the incidence of CK
þ cells in bone marrow.
Immunocytochemical staining with monoclonal antibodies is
commonly accepted as an adequate method to examine the presence
of ITC in blood and bone marrow. Such assays using CK markers for
Table 1 Incidence of ITC before and after chemotherapy
Blood Bone marrow
Blood and/or
bone marrow
ITC Before After Before After Before After
Negative 25 (78%) 27 (84%) 1 (3%) 15 (47%) 0 (0%) 14 (44%)
Positive 7 (22%) 5 (16%) 31 (97%)* 17 (53%)* 32 (100%)* 18 (56%)*
*Po0.01, Wilcoxon-matched pairs test.
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Figure 1 Overall survival by response to neoadjuvant chemotherapy.
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sepithelial tumours can detect a single tumour cell against the
background of millions of normal cells. Nevertheless, no definite
diagnostic standard has been established so far and at least several
‘enrichment’ methods have been developed to increase the chance of
detecting malignant cells. Moreover, some authors examining ITC in
the bone marrow of patients with upper gastrointestinal tumours
subject to thoracotomy advocated that rib segment resections rather
than iliac crest aspirates should be used to achieve reliable results
(O’Sullivan et al, 1999; Bonavina et al, 2001; Mattioli et al,2 0 0 1 ) .A s
no sample obtained from healthy individuals has produced a positive
result for CK
þ cells, we believe that the specificity of our assay is
sufficient. Moreover, the use of immunohistochemical and morpho-
logical criteria, as opposed to PCR-based techniques reduces the risk
of false-positive results (Jung et al, 1999). On the other hand,
application of A45-B/B3 antibodies that recognise common epitopes
of CKs increases the possibility of detecting tumour cells. Further-
more, the applied methodology, based on sorting out all leukocytes
(CD45
þ)a n ds e a r c h i n gf o rC K
þ cells among the remaining CD45
 
population, may ‘concentrate’ the presumptive tumour cells and
increase the rate of detection (Pituch-Noworolska et al, 1998, 2007).
The prognostic implications of ITC in patients with tumours of
the gastrointestinal tract are controversial. In gastric cancer, ITC in
the bone marrow were either significantly associated with overall
survival (Jauch et al, 1996), disease-free survival (Gretschel et al,
2006), or were devoid of any prognostic value (de Manzoni et al,
2002). However, the presence of ITC is interesting not only from
the prognostic point of view, but also for their potential predictive
value. The idea of ITC being used as a surrogate marker for
monitoring the effects of chemotherapy is gaining increasing
attention in breast cancer (Slade et al, 2005; Drageset et al, 2006;
Fehm et al, 2006). However, the information available for
gastrointestinal malignancies is scarce. Surprisingly, some authors
suggested that palliative chemotherapy might even increase the
incidence of ITC. Of 42 stage IV patients with colorectal cancer,
62.5% patients with distant metastases and 14.3% with locally
advanced diseases were positive for ITC in blood using a RT-PCR
assay for CK 20 (Staritz et al, 2004). After the first cycle of
chemotherapy, the detection rates in the latter group increased to
62.5%. Moreover, patients responding to chemotherapy showed an
increase in detection rates from 28.5 before to 71.4% after
chemotherapy.
To our knowledge, no study evaluating the effects of preoperative
chemotherapy on ITC in blood and bone marrow of gastric cancer
patients has been undertaken. In a study carried out by Bonavina
et al (2001), the proportion of ITC in the bone marrow of patients
with oesophageal cancer was similar irrespective of whether they
received previous neoadjuvant chemotherapy (80.0%, 12 of 15) or
not (79%, 26 of 33). Similar findings were reported by O’Sullivan
et al (1999) for 50 patients undergoing potentially curative
resections of oesophageal or oesophagogastric malignancies. The
prevalence of ITC in rib marrow of patients given neoadjuvant
chemotherapy (87%, 13 of 15) was similar to that in patients who
underwent surgery only (89%, 31 of 35). Contrary results were
reported in a study on oesophagogastric cancer (Ryan et al, 2004).
Isolated tumour cells were detected in the bone marrow in 42% of
patients (23 of 55) who received neoadjuvant therapy plus surgery,
and in 67% of patients (34 of 51) treated with surgery alone
(P¼0.01). Owing to contradictory results, no clear conclusions can
be formulated for gastric cancer. Moreover, the presence of ITC in
all these studies was examined only once after the completion of
systemic therapy, and thus no exact comparison with the present
study could be made. In this study, repeated examinations of blood
and bone marrow before and after neoadjuvant chemotherapy
provided evidence that chemotherapy reduced the presence of ITC
in 44% of the patients initially positive for blood and/or bone
marrow. Nevertheless, CK
þ cells were still found in more than one-
half of the patients. This is not surprising considering the fact that
most ITC in the bone marrow are assumed to be in a state of
dormancy at the time of chemotherapy, while systemic treatment
eliminates only proliferating cells (Slade et al, 2005). Contrary to
clinical trials in breast cancer, we were unable to demonstrate any
survival benefit of preoperative chemotherapy in the responders
group. This finding is unexpected and challenges the idea of ITC as
a surrogate marker for monitoring the efficacy of chemotherapy in
gastrointestinal malignancies. However, our pilot study involved a
relatively small number of patients and was not aimed at evaluating
survival benefits. Possibly, more recent regimens of chemotherapy
developed for gastric cancer or novel therapies also directed against
quiescent cells could further increase eradication rates for ITC.
In conclusion, preoperative chemotherapy with cisplatin and 5-
FU can significantly reduce the incidence of ITC in patients with
resectable gastric cancer. However, it was not associated with any
clear survival benefit. Therefore, other clinical trials specifically
evaluating this issue are required.
ACKNOWLEDGEMENTS
We wish to thank Ms Ruggiero for skillful technical assistance.
This study was financially supported by the Polish State
Committee for Scientific Research, Grants no. 3P05C 067 13p01,
4P05C 060 16p01, PBZ-091/PO5/2003 and N403 069 31/3155.
Table 2 The clinicopathological variables in patients responding and
non-responding to neoadjuvant chemotherapy
Responders
(n¼14)
Non-responders
(n¼18) P
Gender
Male 7 (50%) 14 (78%) 0.100
a
Female 7 (50%) 4 (22%)
Age, mean (95% CI) 64 (57–70) 60 (54–65) 0.323
b
Tumour location
Upper third 1 (7%) 5 (28%)
Upper/middle third 4 (29%) 2 (11%) 0.176
a
Middle third 2 (14%) 3 (17%) 0.176
a
Middle/lower third 3 (21%) 5 (28%) 0.176
a
Lower third 1 (7%) 3 (17%) 0.176
a
Whole stomach 3 (21%) 0 (0%) 0.176
a
Lauren’s type
Intestinal 3 (21%) 11 (61%) 0.024
a
Diffuse 11 (79%) 7 (39%)
Depth of infiltration
c
T1 1 (7%) 3 (17%) 0.756
a
T2 2 (14%) 4 (22%)
T3 6 (43%) 6 (33%)
T4 5 (36%) 5 (28%)
Nodal status
Negative 4 (29%) 10 (56%) 0.126
a
Metastatic 10 (71%) 8 (44%)
Stage
c
I 2 (14%) 5 (28%) 0.768
a
II 1 (7%) 2 (11%)
III 5 (36%) 5 (28%)
IV 6 (43%) 6 (33%)
Gastrectomy
No 2 (14%) 3 (17%) 0.854
a
Yes 12 (86%) 15 (83%)
Postoperative chemotherapy
d
No 3 (25%) 5 (33%) 0.962
a
Yes 9 (75%) 10 (67%)
aw
2 test.
bMann–Whitney U-test.
cAJCC classification of 2002.
dPatients who
underwent gastrectomy.
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